Polaryx Therapeutics Inc. (PLYX)
Polaryx Therapeutics Inc. (PLYX) Stock Price, Analysis & Data
| Bid | 1.86 |
| Market Cap | 123.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.85M |
| Beta | n/a |
| EPS (ttm) | -0.14 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| P/B (ttm) | 11.87 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 2.93 |
| Volume | 148,298 |
| Avg. Volume (20D) | 196,422 |
| Open | 2.52 |
| Previous Close | 2.50 |
| Day's Range | 2.22 - 2.68 |
| 52-Week Range | 1.86 - 48.91 |
| Analyst | Strong Buy |
| Price Target | 7 (169.23%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PLYX
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combi...
Financial Performance
In 2025, Polaryx Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -8.98M, a decrease of -70.4%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for PLYX stock is "Strong Buy". The 12-month stock price forecast is 7, which is upside of 169.23% from the latest price.
Stock Forecasts